Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
2.8M
-
Shares change
-
-836K
-
Total reported value, excl. options
-
$11.2M
-
Value change
-
-$3.55M
-
Put/Call ratio
-
2.16
-
Number of buys
-
16
-
Number of sells
-
-19
-
Price
-
$4.01
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q3 2021
45 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q3 2021.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.8M shares
of 51.9M outstanding shares and own 5.4% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (788K shares), Ikarian Capital, LLC (311K shares), JACOB ASSET MANAGEMENT OF NEW YORK LLC (275K shares), Manatuck Hill Partners, LLC (273K shares), COOPERMAN LEON G (200K shares), GEODE CAPITAL MANAGEMENT, LLC (168K shares), Stonepine Capital Management, LLC (166K shares), NORTHERN TRUST CORP (85.6K shares), TWO SIGMA ADVISERS, LP (80.6K shares), and TWO SIGMA INVESTMENTS, LP (74.3K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.